JP6771568B2 - 補体活性化を抑制するポリペプチド - Google Patents
補体活性化を抑制するポリペプチド Download PDFInfo
- Publication number
- JP6771568B2 JP6771568B2 JP2018533148A JP2018533148A JP6771568B2 JP 6771568 B2 JP6771568 B2 JP 6771568B2 JP 2018533148 A JP2018533148 A JP 2018533148A JP 2018533148 A JP2018533148 A JP 2018533148A JP 6771568 B2 JP6771568 B2 JP 6771568B2
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- scr1
- fhr1
- mfhr1
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 81
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 76
- 229920001184 polypeptide Polymers 0.000 title claims description 75
- 230000024203 complement activation Effects 0.000 title description 34
- 210000004027 cell Anatomy 0.000 claims description 44
- 230000027455 binding Effects 0.000 claims description 28
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 25
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 claims description 16
- 101150105073 SCR1 gene Proteins 0.000 claims description 16
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 claims description 16
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 15
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 15
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 15
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims description 11
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 claims description 11
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 10
- 208000002780 macular degeneration Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000017169 kidney disease Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000004154 complement system Effects 0.000 claims description 7
- 238000006471 dimerization reaction Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 5
- 206010021263 IgA nephropathy Diseases 0.000 claims description 5
- 230000002949 hemolytic effect Effects 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 108010074405 complement C5b-6 complex Proteins 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000008736 traumatic injury Effects 0.000 claims description 3
- 102000016550 Complement Factor H Human genes 0.000 claims 7
- 108010053085 Complement Factor H Proteins 0.000 claims 7
- 108010071253 factor H-related protein 1 Proteins 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 description 56
- 108090000790 Enzymes Proteins 0.000 description 56
- 229940088598 enzyme Drugs 0.000 description 56
- 102100022133 Complement C3 Human genes 0.000 description 50
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 50
- 239000012636 effector Substances 0.000 description 43
- 230000000295 complement effect Effects 0.000 description 30
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 28
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 28
- 230000002401 inhibitory effect Effects 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 229960002224 eculizumab Drugs 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 230000015556 catabolic process Effects 0.000 description 22
- 238000006731 degradation reaction Methods 0.000 description 22
- 102100035326 Complement factor H-related protein 2 Human genes 0.000 description 21
- 101000878135 Homo sapiens Complement factor H-related protein 2 Proteins 0.000 description 21
- 102220359583 c.7T>G Human genes 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 19
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 description 14
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 108090000056 Complement factor B Proteins 0.000 description 11
- 102000003712 Complement factor B Human genes 0.000 description 11
- 206010018910 Haemolysis Diseases 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000008588 hemolysis Effects 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 230000008021 deposition Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 102100030386 Granzyme A Human genes 0.000 description 8
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 8
- 230000021917 activation of membrane attack complex Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 230000001434 glomerular Effects 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 108010089414 Anaphylatoxins Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 102100039373 Membrane cofactor protein Human genes 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 108010027437 compstatin Proteins 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 102100022002 CD59 glycoprotein Human genes 0.000 description 3
- 101710172562 Cobra venom factor Proteins 0.000 description 3
- 102100030886 Complement receptor type 1 Human genes 0.000 description 3
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000000585 glomerular basement membrane Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000000938 luteal effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 230000008359 toxicosis Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101100390700 Arabidopsis thaliana FH20 gene Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 description 1
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100038651 Four and a half LIM domains protein 1 Human genes 0.000 description 1
- 101710127220 Four and a half LIM domains protein 1 Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100440311 Homo sapiens C5 gene Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 description 1
- 101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000195888 Physcomitrella Species 0.000 description 1
- 241000195887 Physcomitrella patens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101150039984 RCA gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000001707 glomerular endothelial cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000011102 hetero oligomerization reaction Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000016413 regulation of adaptive immune response Effects 0.000 description 1
- 230000028646 regulation of complement activation Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
Description
CPおよびLPが、ある種の認識分子が引き金となって開始されるのに対し、APは常時低レベルで活性である。これは、「チックオーバー」と称されるメカニズムで起こるもので、C3b様分子であるC3(H2O)の内部C3チオエステルが、生体活性形態を形成するよう加水分解されることにより開始される。可溶性のB因子(FB)およびD因子(FD)(これはC3(H2O)結合FBを分解する)が作用して、液相C3転換酵素複合体(C3b(H2O)Bb)が形成され、天然C3分子が切断され、活性化される。活性化されたC3bは、チオエステル含有ドメイン(TEDまたはC3dドメイン)を介して、隣接表面のヒドロキシル基に共有結合する。病原体上で、C3bが、形成された部位のすぐ近くに蓄積し、さらなるC3転換酵素(C3bBb)が形成され、それによって補体活性化が増幅される。C3転換酵素に第2のC3bが結合することにより、C5転換酵素(C3bBbC3b)が形成され、これはC5の、強力な免疫エフェクター分子C5aおよびC5bへの分解を引き起こす。C5bは補体成分C6、C7、C8およびC9を動員してC5b−9終末膜侵襲複合体(MAC)を形成し、その結果、病原体が溶解される(Ricklin et al. 2010, Carroll et al. 2011)。
オプソニン化細胞および病原体の迅速な排除のため、および宿主組織損傷をもたらしうる無制限のAP活性化を最小限にするために、APは精密に制御されなければならない。健康な宿主細胞は通常、カスケードの異なる活性化段階で作用する、補体活性化制御因子(regulator of complement activation)(RCA)ファミリーのいくつもの膜結合または可溶性タンパク質(それらのいくつかは機能が重複しており、いくつかは独特の補体制御特性を有する)によって、補体が仲介する侵襲から保護されている(Zipfel et al. 2009)。
H因子/FHRタンパク質ファミリーは、5つの補体H因子関連タンパク質(FHR)であるFHR1、FHR2、FHR3、FHR4、FHR5、H因子(FH)およびスプライスバリアントであるH因子様タンパク質1(FHL−1)を含む、一群の関連性の高い血漿タンパク質を含む。ファミリーメンバーのそれぞれの単一遺伝子は、RCA遺伝子クラスター内において、ヒト染色体1q32上の個別のセグメント上に位置する(Skerka et al. 2013)。FHは第2経路の主要な制御因子であり、FHRの機能は完全にはわかっていない。FHRタンパク質の相互作用は、細胞表面上での補体制御活性を調節すると考えられている(Jozsi et al. 2015)。さらに、それらのホモおよびヘテロオリゴマー化能により、FHR1、FHR2およびFHR5のリガンドに対する親和性が高められうる。これは、補体活性化の認識および調節におけるファインチューニング様メカニズムとして提唱されている(Jozsi et al. 2015)。しかしながら、FHR1およびFHR2について、FH非依存性のユニークな補体制御特性もいくつか報告されている。FH、FHR1およびFHR2は補体活性化をダウンレギュレートしうるので、病的状態下の補体活性化を調節する手段の有望な候補であると考えられている(Licht et al. 2005, Licht et al. 2006, Skerka et al. 2013, Haffner et al. 2015)。
補体成分およびFHのような制御因子の、突然変異、機能不全多型によって引き起こされるAP制御不全、またはAP活性化を促進する抗体は、非典型溶血性尿毒症症候群(aHUS)(Noris et al. 2009)またはC3腎症(C3G)(Barbour et al. 2013)、加齢黄斑変性症(AMD)(Kawa et al. 2014)または発作性夜間ヘモグロビン尿症(PNH)(Holers 2008)のような疾患との関連性が高い。これら以外にも、IgA腎症(Maillard et al. 2015)、全身性エリテマトーデス(SLE)(Wilson et al. 1976)、虚血−再灌流(IR)傷害または移植片拒絶、関節リウマチ(RA)および他の多くの疾患(Holers 2008)(Ricklin et al. 2013)について、APの病原的役割が示されまたは仮定されている。
aHUSまたはC3Gの治療における確立された治療オプションは限られており、その例には、血漿交換または新鮮凍結血漿(FFP)交換、免疫抑制処置、および腎移植があるが、基礎疾患の再発リスクは高い(Braun et al. 2005, Lu et al. 2012, Cataland et al. 2014, Masani et al. 2014)。補体を標的とする多くの治療法が現在研究段階にあるので、将来、治療オプションに加わるかもしれない(Wagner et al. 2010, Ricklin et al. 2013)。その中で、ヒト化モノクローナル抗C5抗体エクリズマブは、TCC形成を抑制するもので、最近aHUS治療用に承認された(Zimmerhackl et al. 2010)。C3Gに対しては、確立された治療法はまだ無い(Masani et al. 2014)。エクリズマブをC3G患者に適用した場合、部分奏功が一部の患者においてのみ得られている(Bomback et al. 2012)。
(1)抑制性C3転換酵素エフェクタードメインおよび抑制性C5転換酵素(C5結合)エフェクタードメインを含むポリペプチド。
(2)抑制性C3転換酵素エフェクタードメインが、解離促進(decay-accelerating)およびコファクター活性によって、C3転換酵素抑制をもたらす、上記項(1)のポリペプチド。
(3)ポリペプチドが解離促進およびコファクター活性を有する、上記項(1)または(2)のポリペプチド。
(4)抑制性C3転換酵素エフェクタードメインが、H因子(FH)の断片である、上記項(1)〜(3)のいずれかのポリペプチド。
(5)抑制性C3転換酵素エフェクタードメインが、FHのショートコンセンサスリピート(SCR)1−4を含むか、またはFHのSCR1−4からなる、上記項(1)〜(4)のいずれかのポリペプチド。
(6)抑制性C3転換酵素エフェクタードメインが、FHR2のSCR1−4を含むか、またはFHR2のSCR1−4からなる、上記項(1)〜(3)のいずれかのポリペプチド。
(7)抑制性C5転換酵素エフェクタードメインが、H因子関連タンパク質1(FHR1)の断片である、上記項(1)〜(6)のいずれかのポリペプチド。
(8)抑制性C5転換酵素エフェクタードメインが、FHR1のSCR1およびSCR2を含むか、またはFHR1のSCR1およびSCR2からなる、上記項(1)〜(7)のいずれかのポリペプチド。
(9)ポリペプチドのC5への結合により、C5の活性化ならびにC5aおよびC5bへの分解が抑制される、上記項(1)〜(8)のいずれかのポリペプチド。
(10)細胞表面に結合することができるドメインをさらに含む、上記項(1)〜(9)のいずれかのポリペプチド。
(11)細胞表面に結合することができるドメインが、FHのSCR19およびSCR20を含む、上記項(1)〜(10)のいずれかのポリペプチド。
(12)ポリペプチドが多量体である、上記項(1)〜(11)のいずれかのポリペプチド。
(13)FHR1のSCR1由来の少なくとも1つの二量体化モチーフを含む、上記項(12)のポリペプチド。
(14)ポリペプチドがTCC(C5b−9)の形成を抑制することができる、上記項(1)〜(13)のいずれかのポリペプチド。
(15)ポリペプチドのC5b−6への結合によりTCC形成が抑制される、上記項(14)のポリペプチド。
(16)構造:
A−B−C
[ここで、
Aは、上記項(1)〜(15)のいずれかにおいて規定される抑制性C5転換酵素エフェクタードメインであり、
Bは、上記項(1)〜(15)のいずれかにおいて規定される抑制性C3転換酵素エフェクタードメインであり、
Cは、存在しないか、または、上記項(1)〜(15)のいずれかにおいて規定される、細胞表面に結合することができるドメインである]
を有するポリペプチド。
(17)AとBが直接に、またはリンカーを介して結合している、上記項(16)のポリペプチド。
(18)BとCが直接に、またはリンカーを介して結合している、上記項(16)または(17)のポリペプチド。
(19)補体系が関連または関与する障害の治療または予防において使用するための、上記項(1)〜(18)のいずれかのポリペプチド。
(20)補体系が関連または関与する障害が、非典型溶血性尿毒症症候群(aHUS)、血栓性微小血管症(TMA)、C3腎症(C3G)、IgA腎症、全身性エリテマトーデスの腎炎、移植片拒絶、発作性夜間ヘモグロビン尿症(PNH)、加齢黄斑変性症(AMD)、感染性疾患、敗血症、SIRS、外傷性傷害、虚血/再灌流傷害、および心筋梗塞からなる群から選択される、上記項(19)に記載される使用のためのポリペプチド。
(21)上記項(1)〜(18)のいずれかのポリペプチドをコードする核酸。
(22)上記項(21)の核酸を含むプラスミドまたはベクター。
(23)上記項(21)の核酸、または上記項(22)のプラスミドもしくはベクターを含む細胞。
(24)上記項(1)〜(18)のいずれかのポリペプチドを製造する方法であって、上記項(23)の細胞を、該ポリペプチドの発現を可能にする条件下に培地中で培養し、該細胞または該培地から該ポリペプチドを回収することを含む方法。
本発明は、抑制性C3転換酵素エフェクタードメイン、抑制性C5転換酵素エフェクタードメイン(C5結合ドメイン)、および場合により抑制性TCC形成ドメインおよび/または二量体化モチーフを含むポリペプチドに関する。
Claims (18)
- H因子(FH)のショートコンセンサスリピート(SCR)1−4、H因子関連タンパク質1(FHR1)のSCR1およびSCR2、ならびに細胞表面に結合することができるドメインを含むポリペプチド。
- 細胞表面に結合することができるドメインが、FHのSCR19およびSCR20を含む、請求項1に記載のポリペプチド。
- ポリペプチドが多量体である、請求項1または2に記載のポリペプチド。
- FHR1のSCR1由来の少なくとも1つの二量体化モチーフを含む、請求項3に記載のポリペプチド。
- ポリペプチドがTCC(C5b−9)の形成を抑制することができる、請求項1〜4のいずれかに記載のポリペプチド。
- ポリペプチドのC5b−6への結合によりTCC形成が抑制される、請求項5に記載のポリペプチド。
- 構造:
A−B−C
[ここで、
Aは、FHR1のSCR1およびSCR2を含むか、またはFHR1のSCR1およびSCR2からなり、
Bは、FHのSCR1−4を含むか、またはFHのSCR1−4からなり、
Cは、細胞表面に結合することができるドメインである]
を有するポリペプチド。 - 細胞表面に結合することができるドメインが、FHのSCR19およびSCR20を含む、請求項7に記載のポリペプチド。
- AとBが直接に、またはリンカーを介して結合している、請求項7または8に記載のポリペプチド。
- BとCが直接に、またはリンカーを介して結合している、請求項7〜9のいずれかに記載のポリペプチド。
- FHのSCR1−4が配列番号1のアミノ酸19〜264からなる、請求項1〜10のいずれかに記載のポリペプチド。
- FHR1のSCR1およびSCR2が配列番号2のアミノ酸22〜142からなる、請求項1〜11のいずれかに記載のポリペプチド。
- 補体系が関連または関与する障害を治療または予防するための、請求項1〜12のいずれかに記載のポリペプチドを有効成分として含む医薬組成物。
- 補体系が関連または関与する障害が、非典型溶血性尿毒症症候群(aHUS)、血栓性微小血管症(TMA)、C3腎症(C3G)、IgA腎症、全身性エリテマトーデスの腎炎、移植片拒絶、発作性夜間ヘモグロビン尿症(PNH)、加齢黄斑変性症(AMD)、感染性疾患、敗血症、SIRS、外傷性傷害、虚血/再灌流傷害、および心筋梗塞からなる群から選択される、請求項13に記載の医薬組成物。
- 請求項1〜12のいずれかに記載のポリペプチドをコードする核酸。
- 請求項15に記載の核酸を含むプラスミドまたはベクター。
- 請求項15に記載の核酸、または請求項16に記載のプラスミドもしくはベクターを含む細胞。
- 請求項1〜12のいずれかに記載のポリペプチドを製造する方法であって、請求項17に記載の細胞を、該ポリペプチドの発現を可能にする条件下に培地中で培養し、該細胞または該培地から該ポリペプチドを回収することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102015016665 | 2015-12-23 | ||
DE102015016665.4 | 2015-12-23 | ||
PCT/EP2016/082614 WO2017109208A1 (en) | 2015-12-23 | 2016-12-23 | Polypeptides for inhibiting complement activation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020081070A Division JP2020167999A (ja) | 2015-12-23 | 2020-05-01 | 補体活性化を抑制するポリペプチド |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019508022A JP2019508022A (ja) | 2019-03-28 |
JP6771568B2 true JP6771568B2 (ja) | 2020-10-21 |
Family
ID=57838331
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018533148A Active JP6771568B2 (ja) | 2015-12-23 | 2016-12-23 | 補体活性化を抑制するポリペプチド |
JP2020081070A Withdrawn JP2020167999A (ja) | 2015-12-23 | 2020-05-01 | 補体活性化を抑制するポリペプチド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020081070A Withdrawn JP2020167999A (ja) | 2015-12-23 | 2020-05-01 | 補体活性化を抑制するポリペプチド |
Country Status (19)
Country | Link |
---|---|
US (2) | US10640540B2 (ja) |
EP (1) | EP3394089B1 (ja) |
JP (2) | JP6771568B2 (ja) |
KR (1) | KR20180091097A (ja) |
CN (1) | CN108699121B (ja) |
AU (1) | AU2016375183B2 (ja) |
BR (1) | BR112018012844A2 (ja) |
CA (1) | CA3009393C (ja) |
DK (1) | DK3394089T3 (ja) |
ES (1) | ES2895256T3 (ja) |
HR (1) | HRP20211608T1 (ja) |
HU (1) | HUE056019T2 (ja) |
IL (1) | IL260182B2 (ja) |
LT (1) | LT3394089T (ja) |
MX (1) | MX2018007392A (ja) |
PL (1) | PL3394089T3 (ja) |
PT (1) | PT3394089T (ja) |
SI (1) | SI3394089T1 (ja) |
WO (1) | WO2017109208A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117338781A (zh) * | 2017-08-31 | 2024-01-05 | 诺华股份有限公司 | 哌啶基-吲哚衍生物的用途 |
US20200262879A1 (en) | 2017-09-11 | 2020-08-20 | Insideoutbio, Inc. | Methods and compositions to enhance the immunogenicity of tumors |
US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
DE102018120016B4 (de) * | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0097440B1 (en) * | 1982-06-14 | 1986-09-24 | The Upjohn Company | Method and kit for removing and assaying complement system fragments |
US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
ZA200807620B (en) * | 2006-03-08 | 2009-12-30 | Archemix Corp | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
CL2008003241A1 (es) | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
NZ614351A (en) | 2008-11-10 | 2015-05-29 | Alexion Pharma Inc | Methods and compositions for treating complement-associated disorders |
JP5740772B2 (ja) * | 2009-08-31 | 2015-07-01 | アイビーシー ファーマスーティカルズ,インコーポレイテッド | 二重特異性免疫サイトカインドック−アンド−ロック(dnl)複合体及びその治療的使用 |
WO2011156356A1 (en) * | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
NZ709997A (en) | 2011-04-08 | 2016-03-31 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
CN102978204B (zh) * | 2011-11-11 | 2018-06-08 | 张康 | Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法 |
WO2013142362A1 (en) * | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
FR3015484A1 (fr) * | 2013-12-20 | 2015-06-26 | Lab Francais Du Fractionnement | Proteines recombinantes possedant une activite de facteur h |
WO2020041644A1 (en) * | 2018-08-22 | 2020-02-27 | Alexion Pharmaceuticals, Inc. | Fusion proteins and methods of treating complement dysregulation using the same |
GB2583560A (en) * | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
WO2020232319A1 (en) * | 2019-05-15 | 2020-11-19 | Insideoutbio, Inc. | Modular therapeutics for the treatment of inflammatory diseases and cancer |
WO2021247487A1 (en) * | 2020-06-01 | 2021-12-09 | Medical University Of South Carolina | Recombinant fusion proteins targeting p-selectin, and methods of use thereof for treating diseases and disorders |
-
2016
- 2016-12-23 MX MX2018007392A patent/MX2018007392A/es unknown
- 2016-12-23 HR HRP20211608TT patent/HRP20211608T1/hr unknown
- 2016-12-23 AU AU2016375183A patent/AU2016375183B2/en active Active
- 2016-12-23 PL PL16828743T patent/PL3394089T3/pl unknown
- 2016-12-23 CA CA3009393A patent/CA3009393C/en active Active
- 2016-12-23 BR BR112018012844A patent/BR112018012844A2/pt active Search and Examination
- 2016-12-23 DK DK16828743.1T patent/DK3394089T3/da active
- 2016-12-23 EP EP16828743.1A patent/EP3394089B1/en active Active
- 2016-12-23 KR KR1020187020929A patent/KR20180091097A/ko not_active Application Discontinuation
- 2016-12-23 CN CN201680075659.0A patent/CN108699121B/zh active Active
- 2016-12-23 HU HUE16828743A patent/HUE056019T2/hu unknown
- 2016-12-23 WO PCT/EP2016/082614 patent/WO2017109208A1/en active Application Filing
- 2016-12-23 LT LTEPPCT/EP2016/082614T patent/LT3394089T/lt unknown
- 2016-12-23 PT PT168287431T patent/PT3394089T/pt unknown
- 2016-12-23 IL IL260182A patent/IL260182B2/en unknown
- 2016-12-23 ES ES16828743T patent/ES2895256T3/es active Active
- 2016-12-23 SI SI201631377T patent/SI3394089T1/sl unknown
- 2016-12-23 US US16/065,272 patent/US10640540B2/en active Active
- 2016-12-23 JP JP2018533148A patent/JP6771568B2/ja active Active
-
2020
- 2020-03-20 US US16/825,711 patent/US11591378B2/en active Active
- 2020-05-01 JP JP2020081070A patent/JP2020167999A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20190300589A1 (en) | 2019-10-03 |
IL260182B2 (en) | 2023-12-01 |
JP2020167999A (ja) | 2020-10-15 |
US20200277347A1 (en) | 2020-09-03 |
CA3009393C (en) | 2023-08-22 |
ES2895256T3 (es) | 2022-02-18 |
AU2016375183A1 (en) | 2018-07-19 |
JP2019508022A (ja) | 2019-03-28 |
KR20180091097A (ko) | 2018-08-14 |
DK3394089T3 (da) | 2021-11-01 |
HRP20211608T1 (hr) | 2022-01-21 |
LT3394089T (lt) | 2021-11-25 |
US10640540B2 (en) | 2020-05-05 |
IL260182A (en) | 2018-07-31 |
MX2018007392A (es) | 2018-08-15 |
WO2017109208A1 (en) | 2017-06-29 |
PT3394089T (pt) | 2021-11-03 |
CA3009393A1 (en) | 2017-06-29 |
EP3394089A1 (en) | 2018-10-31 |
SI3394089T1 (sl) | 2021-12-31 |
BR112018012844A2 (pt) | 2018-12-04 |
EP3394089B1 (en) | 2021-07-28 |
AU2016375183B2 (en) | 2021-01-21 |
CN108699121B (zh) | 2023-07-04 |
CN108699121A (zh) | 2018-10-23 |
US11591378B2 (en) | 2023-02-28 |
HUE056019T2 (hu) | 2022-01-28 |
PL3394089T3 (pl) | 2022-01-17 |
IL260182B1 (en) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6771568B2 (ja) | 補体活性化を抑制するポリペプチド | |
US6846649B1 (en) | Recombinant human mannan-binding lectin | |
Sahu et al. | Structure and biology of complement protein C3, a connecting link between innate and acquired immunity | |
US9650447B2 (en) | Complement receptor 2 (CR2) targeting groups | |
KR20120130748A (ko) | 발작성 야간 혈색소뇨증, 용혈성 빈혈, 및 혈관내 및 혈관외 용혈을 수반한 질환 상태의 치료 | |
JP2020014468A (ja) | H因子活性を有する組換えタンパク質 | |
US9649357B2 (en) | Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) | |
WO2009126346A2 (en) | Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins | |
JP2021527439A (ja) | 補体阻害剤及びその使用 | |
WO2018075462A1 (en) | Compositions and methods for treating and preventing transplant-associated injury | |
JP2019523238A (ja) | 補体阻害剤及びその使用 | |
WO2023197930A9 (zh) | 补体抑制杂合蛋白 | |
BECHERER et al. | Molecular Aspects of C3 Interactions and Structural/Functional Analysis of C3 | |
WO2018075450A1 (en) | Compositions and methods for treating central nervous system injury | |
Abe et al. | Complement in human disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180725 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191002 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200501 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200501 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200519 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200619 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200623 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200902 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200929 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6771568 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |